Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after Lung transplantation

被引:47
作者
Yazdani, Arash [1 ]
Singer, Lianne G. [2 ]
Strand, Vibeke [3 ]
Gelber, Allan C. [4 ]
Williams, Laura [5 ]
Mittoo, Shikha [1 ]
机构
[1] Univ Toronto, Div Rheumatol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Stanford Univ, Sch Med, Div Rheumatol Immunol, Palo Alto, CA 94304 USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Northern Ontario Sch Med, Greater Sudbury, ON, Canada
关键词
lung; interstitial; rheumatoid arthritis; transplantation; survival; HISTOPATHOLOGIC PATTERN; INTERNATIONAL-SOCIETY; PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; HEART; SCLERODERMA; CANDIDATES; PNEUMONIA; PROGNOSIS; SF-36;
D O I
10.1016/j.healun.2014.01.858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD) have increased mortality with limited treatment options. We set out to examine post-transplant survival in RA-ILD patients compared with patients with idiopathic pulmonary fibrosis (IPF) and scleroderma-associated ILD (SSc-ILD). We also describe post-transplant quality of life (QoL) outcomes in RA-ILD. METHODS: A retrospective review was performed on lung transplantation (1989 to 2011) among patients with RA-ILD, IPF (group-matched for age and transplant year) and SSc-ILD. Cumulative survival after transplantation was estimated by the Kaplan-Meier method and compared between groups using the log-rank test. The 36-item Medical Outcomes Survey Short Form (SF-36) and the St. George's Respiratory Questionnaire (SGRQ) scores, before and after lung transplantation, were analyzed. RESULTS: Overall, 10 patients with RA-ILD, 53 with IPF and 17 with SSc-ILD underwent lung transplantation with ages (mean +/- SD) of 59.4 +/- 5.6, 61.0 +/- 4.0 and 45.4 +/- 12.7 years, respectively. Cumulative survival rates at 1-year post-transplant for the RA-ILD, IPF and SSc-ILD groups were 67%, 69% and 82%, respectively, and there was no significant difference among groups in age- and gender-adjusted analyses. Among the RA-ILD patients, mean SF-36 physical component summary scores improved from 22.4 +/- 8.1 to 32.2 +/- 12.9 (p = 0.1), SF-36 mental component summary scores improved from 44.7 +/- 15.3 to 54.9 +/- 4.8 (p = 0.19) and SGRQ total scores improved from 70.4 +/- 16.1 to 36.0 +/- 18.5 (p = 0.03). CONCLUSIONS: After lung transplantation, RA-ILD and IPF patients have similar survival rates. Further, in RA-ILD patients, lung transplantation appears to result in a significant improvement in QoL with regard to respiratory symptoms. These data suggest that lung transplantation should be considered in patients with end-stage RA-ILD. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:514 / 520
页数:7
相关论文
共 50 条
  • [31] Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management
    Dai, Yujie
    Wang, Weina
    Yu, Yikai
    Hu, Shaoxian
    CLINICAL RHEUMATOLOGY, 2021, 40 (04) : 1211 - 1220
  • [32] Reinterpreting Evidence of Rheumatoid Arthritis-Associated interstitial Lung Disease to Understand Etiology
    Wu, Emily K.
    Ambrosini, Robert D.
    Kottmann, R. Matthew
    Ritchlin, Christopher T.
    Schwarz, Edward M.
    Rahimi, Homaira
    CURRENT RHEUMATOLOGY REVIEWS, 2019, 15 (04) : 277 - 289
  • [33] Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality
    Hyldgaard, Charlotte
    Ellingsen, Torkell
    Hilberg, Ole
    Bendstrup, Elisabeth
    RESPIRATION, 2019, 98 (05) : 455 - 460
  • [34] Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist?
    Akiyama, Mitsuhiro
    Alshehri, Waleed
    Kaneko, Yuko
    AUTOIMMUNITY REVIEWS, 2024, 23 (02)
  • [35] Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease
    Zamora-Legoff, Jorge A.
    Krause, Megan L.
    Crowson, Cynthia S.
    Ryu, Jay H.
    Matteson, Eric L.
    CLINICAL RHEUMATOLOGY, 2016, 35 (10) : 2585 - 2589
  • [36] MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease
    Klein, Jacob
    Wheeler, Austin M.
    Baker, Joshua F.
    Yang, Yangyuna
    Roul, Punyasha
    Frideres, Halie
    Wysham, Katherine D.
    Kerr, Gail S.
    Reimold, Andreas
    Ascherman, Dana P.
    Kunkel, Gary A.
    Cannon, Grant W.
    Monach, Paul A.
    Poole, Jill A.
    Thiele, Geoffrey M.
    Mikuls, Ted R.
    England, Bryant R.
    RHEUMATOLOGY, 2024,
  • [37] Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease
    Ota, Mineto
    Iwasaki, Yukiko
    Harada, Hiroaki
    Sasaki, Oh
    Nagafuchi, Yasuo
    Nakachi, Shinichiro
    Sumitomo, Shuji
    Shoda, Hirofumi
    Tohma, Shigeto
    Fujio, Keishi
    Yamamoto, Kazuhiko
    MODERN RHEUMATOLOGY, 2017, 27 (01) : 22 - 28
  • [38] Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease
    Nurmi, Hanna M.
    Kettunen, Hannu-Pekka
    Suoranta, Sanna-Katja
    Purokivi, Minna K.
    Karkkainen, Miia S.
    Selander, Tuomas A.
    Kaarteenaho, Riitta L.
    RESPIRATORY MEDICINE, 2018, 134 : 24 - 30
  • [39] Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease
    Juge, Pierre-Antoine
    Hayashi, Keigo
    McDermott, Gregory C.
    Vanni, Kathleen M. M.
    Kowalski, Emily
    Qian, Grace
    Bade, Katarina
    Saavedra, Alene
    Dieude, Philippe
    Dellaripa, Paul F.
    Doyle, Tracy J.
    Sparks, Jeffrey A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 64
  • [40] Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening
    Narvaez, Javier
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)